Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose sirolimus plus low-dose Advagraf versus standard-dose Advagraf after liver transplantation for renal protection
NL-OMON26731Phase 3Not yet recruiting
- Sponsor
- Foundation for Liver and Gastrointestinal Research
- Start
- Oct 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus and tacrolimus in liver transplant, sponsored by Foundation for Liver and Gastrointestinal Research. Primary endpoint: Percentage of patients with cGFR < 60 mL/min at 36 months after transplantation. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
sirolimustacrolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on NL-OMON26731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26731.